參考文獻(xiàn)/References:
[1] SUN H,SAEEDI P,KARURANGA S,et al.IDF diabetes atlas:global,regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J].Diabetes Res Clin Pract,2022,183:109119.
[2] YUAN S,LARSSON S C.Epidemiology of sarcopenia:prevalence,risk factors,and consequences[J].Metabolism,2023,144:155533.
[3] JIANG W,ZHAN W,ZHOU L,et al.Potential therapeutic targets for sarcopenia identified by Mendelian randomisa-tion[J].Age Ageing,2023,52(2):afad024.
[4] 周曉寧,許金海,王國(guó)棟,等.肌少癥治療[J].中華骨質(zhì)疏松和骨礦鹽疾病雜志,2020,13(3):272-279.
[5] 張桂仙,袁婭金,熊薇,等.基于PI3K/Akt信號(hào)通路預(yù)防治療2型糖尿病肌少癥研究進(jìn)展[J].中國(guó)老年學(xué)雜志,2021,41(5):1110-1115.
[6] XU Y,HU T,SHEN Y,et al.Association of skeletal muscle mass and its change with diabetes occurrence:a population-based cohort study[J].Diabetol Metab Syndr,2023,15(1):53.
[7] WU T H,TSAI S C,LIN H W,et al.Increased serum levels of advanced glycation end products are negatively associated with relative muscle strength in patients with type 2 diabetes mellitus[J].BMC Endocr Disord,2022,22(1):118.
[8] GAN Z,FU T,KELLY D P,et al.Skeletal muscle mitochondrial remodeling in exercise and diseases[J].Cell Res,2018,28(10):969-980.
[9] MENG S J,YU L J.Oxidative stress,molecular inflammation and sarcopenia[J].Int J Mol Sci,2010,11(4):1509-1526.
[10] CHENG T L,LIN Z Y,LIAO K Y,et al.Magnesium lithospermate B attenuates high-fat diet-induced muscle atrophy in C57BL/6J mice[J].Nutrients,2021,14(1):104.
[11] 王琪,雷濤,徐媛穎,等.2型糖尿病合并肌少癥發(fā)病機(jī)制及中醫(yī)藥治療進(jìn)展[J].山東中醫(yī)藥大學(xué)學(xué)報(bào),2022,46(1):129-136.
[12] TRIERWEILER H,KISIELEWICZ G,HOFFMANN JONASSON T,et al.Sarcopenia:a chronic complication of type 2 diabetes mellitus[J].Diabetol Metab Syndr,2018,10:25.
[13] 楊琴.2型糖尿病和糖尿病足病人群中糖尿病周圍神經(jīng)病變與肌少癥的相關(guān)性研究[D].重慶:重慶醫(yī)科大學(xué),2020.
[14] 吳巧.老年2型糖尿病患者慢性并發(fā)癥與肌肉量減少的相關(guān)性研究[D].南京:東南大學(xué),2019.
[15] 柳楊青.肌肉生長(zhǎng)抑制素對(duì)2型糖尿病小鼠胰島素抵抗及骨骼肌胰島素信號(hào)通路的影響[D].開封:河南大學(xué),2020.
[16] 王冰清,章聯(lián)歡,馮夢(mèng)雪,等.基于《金匱要略》虛勞理論探討肌少癥的辨治[J].浙江中西醫(yī)結(jié)合雜志,2021,31(6):579-580.
[17] 孫粼,陳川,陳久林,等.“補(bǔ)腎還精方”治療老年衰弱綜合征47例臨床研究[J].江蘇中醫(yī)藥,2024,56(2):37-40.
[18] 蘇麒麟,孫鑫,楊芳,等.補(bǔ)腎中藥對(duì)絕經(jīng)后骨質(zhì)疏松癥模型大鼠骨及肌肉組織Notch信號(hào)通路蛋白表達(dá)的影響[J].中華中醫(yī)藥雜志,2016,31(8):3208-3212.
[19] 黃研,邢三麗,胡怡然,等.補(bǔ)腎還精方通過調(diào)節(jié)鐵死亡干預(yù)小鼠肌少癥的效應(yīng)和機(jī)制研究[J].上海中醫(yī)藥雜志,2022,56(7):74-82.
[20] ZUO X Y,YAO R F,ZHAO L Y,et al.Campanumoea javanica Bl.activates the PI3K/AKT/mTOR signaling pathway and reduces sarcopenia in a T2DM rat model[J].Acupuncture and Herbal Medicine,2022,2(2):99-108.
[21] 高瑋男.人參皂苷Rb1激活PI3K/AKT/PGC1α信號(hào)通路提高小鼠骨骼肌運(yùn)動(dòng)耐力的研究[D].長(zhǎng)春:吉林大學(xué),2022.
[22] 歐莉,康文倩,梁子怡,等.黃芪對(duì)廢用性大鼠骨骼肌萎縮的影響及其作用機(jī)制研究[J].吉林中醫(yī)藥,2022,42(7):808-811.
[23] 邢中夫,于慧,萬新煥.淫羊藿多糖提取、分離純化、結(jié)構(gòu)特征和生物活性研究進(jìn)展[J].藥學(xué)研究,2023,42(10):830-836.
[24] 陳娟,郭小紅,張小瓊,等.仙茅化學(xué)成分、藥理與毒理作用研究進(jìn)展[J].中華中醫(yī)藥雜志,2021,36(7):4151-4158.
[25] 朱維懿.淫羊藿苷通過調(diào)節(jié)自噬穩(wěn)態(tài)治療小鼠骨骼肌減少癥的機(jī)制研究[D].上海:上海中醫(yī)藥大學(xué),2020.
[26] 陳穎穎,何緒屏.健脾補(bǔ)腎法改善老年糖尿病肌少癥患者胰島素抵抗的臨床研究[J].中國(guó)醫(yī)藥科學(xué),2020,10(19):214-216.
[27] 趙俊.補(bǔ)腎健脾方治療陽虛型肌少癥的臨床研究[D].天津:天津中醫(yī)藥大學(xué),2020.
[28] 金曄華,徐劃萍,金國(guó)琴,等.補(bǔ)腎健脾方對(duì)地塞米松誘導(dǎo)大鼠骨骼肌萎縮的影響[J].中國(guó)老年學(xué)雜志,2017,37(1):13-15.
[29] 宋清揚(yáng),王小星,牛秀茹,等.自擬健脾益腎方治療老年骨骼肌減少癥脾腎兩虛、寒濕內(nèi)蘊(yùn)證臨床研究[J].國(guó)際中醫(yī)中藥雜志,2020,42(8):733-736.
[30] 馬文影,霍晶晶.血府逐瘀湯治療糖尿病及其慢性并發(fā)癥與合并癥的臨床整合證據(jù)鏈[J].中國(guó)醫(yī)學(xué)創(chuàng)新,2022,19(1):175-178.